Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension Accepted: November 14, 2013 1421-9778/14/0331-0088$39.50/0 This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Original Paper
The Gene Polymorphism of LOX1 Predicts the Incidence of LVH in Patients with Essential Hypertension Xiaolin Xua Xuwei Houb Yixiu Liangc Fan Lid Liewen Panga Guoqian Huanga Jiechun Huanga Meng Shia Xiaotian Suna Yiqing Wanga Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, bDepartment of Cardiology, Nanjing Medical University, Hangzhou, cDepartment of Cardiology, Zhongshan Hospital, Fudan University, dDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China a
Key Words Lectin-like oxidized low-density lipoprotein receptor-1 • Essential hypertension • Left ventricular hypertrophy • SNP Abstract Background: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) has been shown to play an important role in cardiac remodeling under different pathologic conditions. The role of genetic polymorphisms in the LOX1 gene, however, remains unclear in the development of left ventricular hypertrophy (LVH) for patients with hypertension. Methods: A total of 536 patients diagnosed with essential hypertension (EH) were recruited in this study. Patients were assigned to the LVH+ (n=143) and LVH- (n=393) groups, respectively. The serum LOX1 level was measured and three single nucleotide polymorphisms (SNPs), i.e. intron 4 (G→A), intron 5(T→G), and 3′ UTR (T→C) of the LOX1 gene were genotyped. Results: The genotype frequencies of intron 4 G>A and 3′UTR T>C were not significantly different between the LVH+ and LVH- groups (both P>0.05), however, frequencies of 501G>C were significantly different between those two groups (P=0.007). The 501CC genotype carriers had a markedly higher serum LOX1 level and an increased risk to develop LVH (adjusted OR=2.444, adjusted P=0.002). There was a positive correlation between serum LOX1 level and left ventricular mass index (r=0.907, PC SNP in the LOX1 gene and the serum LOX1 level may be used to predict the development of LVH among EH patients. Copyright © 2014 S. Karger AG, Basel Yiqing Wang
12 Urumchi, Jing’An district, Shanghai 200040 (China) Fax +86 21 52887075, E-Mail [email protected]
88
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Introduction
Hypertension is a major etiological factor for left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) has been considered as an independent risk factor of cardiovascular events and death [1-5]. Epidemiological studies show that the prevalence of left ventricular hypertrophy (LVH) in Chinese patients with essential hypertension (EH) was about 25% to 35% [6]. A number of environmental factors, including blood pressure level, duration of hypertension, age, obesity, and smoking status have been shown to contribute to the incidence of LVH in human [7-10]. Epidemiological studies have also showed that the individual genetic background plays an important role in the incidence of LVH [11, 12]. A variety of studies suggested the polymorphisms of candidate genes may be used as molecular markers to predict the LVH [13-17]. Unfortunately, the results of these studies are often inconsistent or even controversial. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor of oxidized low-density lipoproteins (ox-LDL) which regulates growth of a variety of cells and is important in inflammation, atherosclerosis, oxidative stress, and tissue remodeling [18-21]. LOX-1 is expressed in various cells, including endothelial cells, macrophages, and chondrocytes, and its expression is enhanced by proinflammatory cytokines [22]. A recent study showed that LOX-1 is a key modulator of the development of angiotensin IIinduced hypertension and subsequent cardiac remodeling [23]. LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion [24]. LOX-1 also affects cardiac fibroblast growth and collagen secretion [25]. The LOX1 gene, also known as OLR1, is located on the chromosome 12p13.1-p12.3. The LOX1 protein is synthesized as a 40-kDa precursor protein and is composed of four domains: an extracellular lectin-like domain at the C-terminal, a connecting neck domain, a transmembrane domain, and an N-terminal cytoplasmic domain [26]. Three single nucleotide polymorphism (SNPs), namely, intron 4 (G→A), intron 5(T→G), and 3′ UTR (T→C) in the LOX1 gene, have been previously reported [27]. Hou et al. reported that the LOX1 polymorphism is closely related to the serum CRP levels and the occurrence of albuminuria in Chinese hypertensive patients [28, 29], suggesting the potential application of the LOX1 polymorphism as a molecular marker for hypertension-related complications. However, the association between the LOX1 polymorphisms and LVH in hypertensive subjects has not yet been reported. Given the role of LOX1 in the cardiac remodeling [2325] , we postulate that the LOX1 gene polymorphisms may affect the occurrence of LVH in hypertensive patients. In this hospital-based case-control study, we enrolled EH patients to test this hypothesis. Materials and Methods
Patient enrollment A total of 536 patients diagnosed with EH in our hospital were recruited between April 2007 and September 2011. According to the presence or absence of LVH, subjects were divided into the LVH+ (EH with LVH, n=143) and LVH- (EH without LVH, n=393) groups. In order to avoid the effects of drug therapy on LVH, patients were matched by the baseline antihypertensive therapy and disease duration. The baseline therapy includes the angiotension converting enzyme inhibitors (ACEI), calcium-channel blocker (CCB), Angiotension II Type 1 Receptor Blocker (AT1 RB), β receptor blocker, and diuretics. Those who with secondary arterial hypertension, congenital heart disease, dilated, hypertrophic or restrictive cardiomyopathy, valvular heart diseases, pulmonary hypertension, coronary heart disease (including Ischemic cardiomyopathy), severe heart failure, lipid metabolism disorders, acute and chronic liver disorders were excluded. All patients were provided with an informed written consent. The study protocol was approved by the ethics committee in our hospital. The clinical variables including diabetes mellitus (DM), alcohol intake, smoking status, weight, height, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were acquired
89
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
from the medical charts. The levels of serum creatinine (sCr), total cholesterol (TC), total triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and blood glucose were acquired.
The measurements of High-sensitivity C-reactive protein (hs-CRP) and serum LOX1 The measurement of High-sensitivity C-reactive protein (hs-CRP) was performed using a commercially available high-sensitivity assay (Roche Diagnostics). Serum sLOX-1 levels were measured by a commercially available enzyme-linked immunosorbent assay kit. The assay is sensitive to the sLOX-1 level of 2.4 pg/mL and above with a coefficient of variation 49.2 g/2.7 m for men and >46.7 g/2.7 m for women [16]. The echocardiography measurement was performed by two experienced echo doctors who were blind to the study protocols. The intra-observer correlation coefficiency for two investigators was 0.925 and 0.903, respectively (both P 0.05). The genotype and allele frequencies of the intron 4 G>A and 3′UTR T>C SNPs were not significantly different between the LVH+ and LVH- groups (P>0.05). However, the genotype and allele frequencies of the 501G>C SNP were significantly different between those two groups. LVH+ patients had a markedly higher frequency of CC genotype than LVH- patients (60% vs.49 %, P=0.007). With the 501GG genotype as reference, multivariate logistic regression analysis showed that the 501CC genotype carriers had a markedly higher risk to develop LVH (adjusted OR=2.444, 95% CI:1.39-4.28, adjusted P=0.002) after adjustment for age, sex, alcohol intake, smoking status, BMI, TG, TC, HDL ,LDL, sCr , BP levels, hs-CRP and sLOX1 levels. The C allele carriers represented a significantly lower risk of developing LVH after adjustment of the above mentioned clinical variables (adjusted OR=1.571, adjusted PA and 3′UTR T>C, and the occurrence of LVH (all P>0.05).
90
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Table 1. The clinical and biochemical characteristic of all enrolled patients is shown in Table 1
Table 2.The genotypes and the allele frequencies of LOX1 gene in two groups
LOX1 haplotypes and LVH The associations between the LOX1 haplotypes and the LVH status were also explored in this study. The D´ value for the studied 3 SNPs was calculated using the SHEsis software. All 3 SNPs were in strong LD (all D´>0.8). The estimated haplotype frequencies of the LOX1
91
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Table 3. LOX1 haplotypes and LVH. (All those frequencyC polymorphism was significantly correlated with the levels of sLOX1 and hs-CRP in this study. The 501CC genotype carriers had markedly increased levels of sLOX1 and hs-CRP compared to the 501GG and 501GC carriers (all PT SNP is located at the 3’ untranslated region of mRNA that has been shown to modulate the regulation of gene expression [27]. Its correlation to severity of AMI and CAD has also been proposed according to a number of research studies [27, 33, 34]. The intron 4 G>A SNP has been previously studied due to its occurrence in linkage disequilibrium (LD) with the 501 G>C and 3’UTR C>T SNPs in the OLR1 gene [30]. The association of polymorphisms of the OLR1 gene and risks to develop vascular diseases, however, is still inconclusive. The 501G>C SNP, for example, failed to show correlation in the development of the ischemic cerebrovascular diseases (CVD) [36]. Our study was not able to establish the statistical association between the SNPs, Intron 4 and 3’UTR, and LVH in the EH patients. This may be due to the size of sample that did not reach the power of calculation. In line with a report from Chen et al., three SNPs we studied were in significant LD and were presented with similar allele frequencies (i.e., Intron 4>G 48.3%, 501 >G 48% and 3’UTR >T 48%). These frequencies are comparable to data generated from studies on non-Hispanic white populations, neverthelss, vastly different from the African American populations [27]. Evidence of LD has been widely reported between the polymorphisms of the LOX1 gene. Three common haplotypes account for 85% of the observed OLR1 haplotypes among the Centre d'Etude du Polymorphisme Humain (CEPH) individuals, who are representative of the European American population from the HapMap project (10 SNPs) [37]. Three LD blocks have been described [30]. Here, we, for the first time, report the similar allele frequencies of the intron 4 G>A, 501 G>C and 3’UTR C>T SNPs in the LOX1 gene between the Chinese population and certain Western population. In addition, the haplotypes (intron 4-501-3’UTR), A-C-C and G-C-T, showed significant correlation to the development of LVH in EH patients, which is consistent with the finding that the LVH+ patients had a markedly higher frequency of the CC genotype compared to the LVH- patients (P=0.007). This may provide evidence of using the 501 G>C SNP as a solo genetic marker to monitor the EH patients for their risk to develop LVH. We also found that the LOX1 501CC genotype carriers had significantly increased sLOX1 and hs-CRP levels compared to the 501GG and 501GC carriers. Furthermore, not only the sLOX but also the hs-CRP levels were significantly higher in the LVH+ group compared to the LVH- group. The sLOX-1 level, however, may be a better parameter than hs-CRP to
93
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
differentiate the LVH+ patients from the LVH- patients based on the ROC curves. These experimental results correlate to close functional partnership of LOX1 and CRP that has been well studied in their pro-atherogenic effects on vascular cells [16, 38-41]. Among all, a recent study suggested that L5, a subfraction of plasma LDL, CRP and the LOX-1 may constitute a positive feedback loop that contributes to endothelial dysfunction [39]. LOX-1 along with Fcγ receptors functions as a receptor for CRP [42]. CRP elicits oxidative stress and compromises vasomotor function on porcine coronary arterioles via LOX-1 activation [38]. In addition, CRP promotes the release of soluble LOX-1 from macrophages by activating tumor necrosis factor alpha (TNF-α) converting enzyme [39] and increases vascular permeability through direct binding to LOX-1[42]. On the other hand, LOX-1 mediated upregulation of a thrombogenic protein, plasminogen activator inhitor-1 (PAI-1) in arterioles by CRP [38]. LOX-1 may be also involved in CRP-induced complement activation, and thus may serve to locate the site of CRP-induced complement activation and inflammation [42]. Those emerging pieces of evidence could facilitate our understanding to the mechanisms involved in the regulation of the LOX1 501 SNP on the sLOX1 and hs-CRP levels among EH patients. Several limitations should be addressed in this study. Firstly, this is a single center study on the Chinese population. A validation cohort is necessary to confirm the association between the serum LOX1 levels and the LOX1 SNPs among EH patients with LVH. Secondly, the findings of this study only indicate the association between the LOX1 polymorphisms and the serum LOX1 levels among EH patients with already developed LVH. Ideally, the longitudinal echocardiography data is required to determine if a genotype as a biomarker is predictive of the progression and development of LVH in EH patients. Taken together, data from our study indicates that the LOX1 501 >C SNP as well as the LOX1 haplotypes, A-C-C and G-C-T, which carry this particular SNP, are significantly associated with the incidence of LVH among the EH patients. The sLOX-1 level may also serve as a biomarker to monitor EH patients in the development of LVH. Both the prospective and larger scale studies are warranted to verify our findings in order to apply into clinical practice. References
1
2 3 4
5 6
7
8
Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R: Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008;26:1602-1611. Petrovic D, Stojimirovic B: [Left ventricular hypertrophy in patients treated with regular hemodialyses]. Med Pregl 2008;61:369-374. Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 1994;8:S549-556. Tovillas-Moran FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, Dalfo-Baque A, Galceran JM, Coca A: [Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care]. Med Clin (Barc) 2010;135:397-401. Wang Y, Hou X, Li Y: Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects. J Biomed Sci 2010;17:23. Zhan S, Liu M, Yao W, Hu Y, Li L, Zhu G, Sun N, Dai L: [Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2002;23:182-185. Varis JP, Puukka PJ, Karanko HM, Jula AM: Risk assessment of echocardiographic left ventricular hypertrophy with electrocardiography, body mass index and blood pressure. Blood Press doi:10.3109/080 37051.2013.803313. McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, Sorof JM, Portman RJ: Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension 2007;50:392-395.
94
Cellular Physiology and Biochemistry 9 10 11
12 13 14
15 16
17
18 19 20
21
22
23
24
25
26
27
28
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Bangalore S, Yao SS, Chaudhry FA: Usefulness of stress echocardiography for risk stratification and prognosis of patients with left ventricular hypertrophy. Am J Cardiol 2007;100:536-543. Koziolova NA, Shatunova IM, Lazarev IA: [Risk factors of development of left ventricular hypertrophy in patients with hypertensive disease with high compliance to treatment]. Kardiologiia 2012;52:25-30. Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin-Duran R, Hurle MA, Nistal JF: Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009;46:526-535. Mirotsou M, Dzau VJ, Pratt RE, Weinberg EO: Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol Genomics 2006;27:86-94. Kurbanova D, Eliseyeva M: Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars 2010;38:466-472. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA: Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest 2013; 73:75-81. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS, Ferrante AW, Mital S: Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 2008;14:760-767. Xu HY, Hou XW, Wang LF, Wang NF, Xu J: Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010;335:13-17. Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S: Protective role of granulocyte colonystimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 2009;187:40-44. Inoue N, Fujita Y, Sawamura T: [Progress in the research on Lox-1 and its clinical relevance]. Nihon Yakurigaku Zasshi 2006;127:103-108. Al-Banna N, Lehmann C: Oxidized LDL and LOX-1 in experimental sepsis. Mediators Inflamm 2013;2013:761789. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T: Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-294. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colonystimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100:899-902. Kang BY, Hu C, Ryu S, Khan JA, Biancolella M, Prayaga S, Seung KB, Novelli G, Mehta P, Mehta JL: Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics 2010;42:42-54. Hu C, Dandapat A, Chen J, Fujita Y, Inoue N, Kawase Y, Jishage K, Suzuki H, Sawamura T, Mehta JL: LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res 2007;76:292-302. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, Mehta JL: Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 2008;283:10226-10231. Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H, Masaki T: Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene. Biochem J 1999;339:177-184. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, McNamara DM, Pauly DF, Sharaf B, Holubkov R, Bairey Merz CN, Sopko G, Bontempo F, Kamboh MI: Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003;107:3146-3151. Hou XW, Yang RQ, Zhong YG, Gao W, Sun SP, Wang NF: G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 2011;10.
95
Cellular Physiology and Biochemistry 29
30
31 32 33
34
35
36 37 38 39
40
41
42
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Hou XW, Wang LF, Wang N, Pang D, Hui B, Zhou YL, He X: The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta 2008;388:200-203. Trabetti E, Biscuola M, Cavallari U, Malerba G, Girelli D, Olivieri O, Martinelli N, Corrocher R, Pignatti PF: On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 2006;14:127-130. Li JJ, Chen JL: Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005;64:925-929. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003;12:181-187. Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S, Kawana M, Masaki T, Kasanuki H, Sawamura T, Matsuoka R: Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-250. Ohmori R, Momiyama Y, Nagano M, Taniguchi H, Egashira T, Yonemura A, Nakamura H, Kondo K, Ohsuzu F: An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 2004;27:641-644. Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi-Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, Tate S: Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 2005;13:905-917. Hattori H, Sonoda A, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N: G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res 2006;1121:246-249. Meucci MA, Marsh S, Watters JW, McLeod HL: CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 2005;6:59-63. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L: Selective Activation of LOX-1 Mediates C-Reactive Protein Evoked Endothelial Vasodilator Dysfunction in Coronary Arterioles. Circ Res 2013;114:92-100. Chu C-S, Wang Y-C, Lu L-S, Walton B, Yilmaz HR, Huang RY, Sawamura T, Dixon RAF, Lai W-T, Chen C-H, Lu J: Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor. PLoS ONE 2013;8:e70533. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH: Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-627. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WS, Yang CY, Chen CH: Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57:158-166. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T: Lectin-like Oxidized LDL Receptor 1 Is Involved in CRP-Mediated Complement Activation. Clin Chem 2011;57:1398-1405.
96
Copyright: S. Karger AG, Basel 2014. Reproduced with the permission of S. Karger AG, Basel. Further reproduction or distribution (electronic or otherwise) is prohibited without permission from the copyright holder.
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension Accepted: November 14, 2013 1421-9778/14/0331-0088$39.50/0 This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Original Paper
The Gene Polymorphism of LOX1 Predicts the Incidence of LVH in Patients with Essential Hypertension Xiaolin Xua Xuwei Houb Yixiu Liangc Fan Lid Liewen Panga Guoqian Huanga Jiechun Huanga Meng Shia Xiaotian Suna Yiqing Wanga Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, bDepartment of Cardiology, Nanjing Medical University, Hangzhou, cDepartment of Cardiology, Zhongshan Hospital, Fudan University, dDepartment of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, Shanghai, China a
Key Words Lectin-like oxidized low-density lipoprotein receptor-1 • Essential hypertension • Left ventricular hypertrophy • SNP Abstract Background: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) has been shown to play an important role in cardiac remodeling under different pathologic conditions. The role of genetic polymorphisms in the LOX1 gene, however, remains unclear in the development of left ventricular hypertrophy (LVH) for patients with hypertension. Methods: A total of 536 patients diagnosed with essential hypertension (EH) were recruited in this study. Patients were assigned to the LVH+ (n=143) and LVH- (n=393) groups, respectively. The serum LOX1 level was measured and three single nucleotide polymorphisms (SNPs), i.e. intron 4 (G→A), intron 5(T→G), and 3′ UTR (T→C) of the LOX1 gene were genotyped. Results: The genotype frequencies of intron 4 G>A and 3′UTR T>C were not significantly different between the LVH+ and LVH- groups (both P>0.05), however, frequencies of 501G>C were significantly different between those two groups (P=0.007). The 501CC genotype carriers had a markedly higher serum LOX1 level and an increased risk to develop LVH (adjusted OR=2.444, adjusted P=0.002). There was a positive correlation between serum LOX1 level and left ventricular mass index (r=0.907, PC SNP in the LOX1 gene and the serum LOX1 level may be used to predict the development of LVH among EH patients. Copyright © 2014 S. Karger AG, Basel Yiqing Wang
12 Urumchi, Jing’An district, Shanghai 200040 (China) Fax +86 21 52887075, E-Mail [email protected]
88
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Introduction
Hypertension is a major etiological factor for left ventricular hypertrophy (LVH). Left ventricular hypertrophy (LVH) has been considered as an independent risk factor of cardiovascular events and death [1-5]. Epidemiological studies show that the prevalence of left ventricular hypertrophy (LVH) in Chinese patients with essential hypertension (EH) was about 25% to 35% [6]. A number of environmental factors, including blood pressure level, duration of hypertension, age, obesity, and smoking status have been shown to contribute to the incidence of LVH in human [7-10]. Epidemiological studies have also showed that the individual genetic background plays an important role in the incidence of LVH [11, 12]. A variety of studies suggested the polymorphisms of candidate genes may be used as molecular markers to predict the LVH [13-17]. Unfortunately, the results of these studies are often inconsistent or even controversial. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor of oxidized low-density lipoproteins (ox-LDL) which regulates growth of a variety of cells and is important in inflammation, atherosclerosis, oxidative stress, and tissue remodeling [18-21]. LOX-1 is expressed in various cells, including endothelial cells, macrophages, and chondrocytes, and its expression is enhanced by proinflammatory cytokines [22]. A recent study showed that LOX-1 is a key modulator of the development of angiotensin IIinduced hypertension and subsequent cardiac remodeling [23]. LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion [24]. LOX-1 also affects cardiac fibroblast growth and collagen secretion [25]. The LOX1 gene, also known as OLR1, is located on the chromosome 12p13.1-p12.3. The LOX1 protein is synthesized as a 40-kDa precursor protein and is composed of four domains: an extracellular lectin-like domain at the C-terminal, a connecting neck domain, a transmembrane domain, and an N-terminal cytoplasmic domain [26]. Three single nucleotide polymorphism (SNPs), namely, intron 4 (G→A), intron 5(T→G), and 3′ UTR (T→C) in the LOX1 gene, have been previously reported [27]. Hou et al. reported that the LOX1 polymorphism is closely related to the serum CRP levels and the occurrence of albuminuria in Chinese hypertensive patients [28, 29], suggesting the potential application of the LOX1 polymorphism as a molecular marker for hypertension-related complications. However, the association between the LOX1 polymorphisms and LVH in hypertensive subjects has not yet been reported. Given the role of LOX1 in the cardiac remodeling [2325] , we postulate that the LOX1 gene polymorphisms may affect the occurrence of LVH in hypertensive patients. In this hospital-based case-control study, we enrolled EH patients to test this hypothesis. Materials and Methods
Patient enrollment A total of 536 patients diagnosed with EH in our hospital were recruited between April 2007 and September 2011. According to the presence or absence of LVH, subjects were divided into the LVH+ (EH with LVH, n=143) and LVH- (EH without LVH, n=393) groups. In order to avoid the effects of drug therapy on LVH, patients were matched by the baseline antihypertensive therapy and disease duration. The baseline therapy includes the angiotension converting enzyme inhibitors (ACEI), calcium-channel blocker (CCB), Angiotension II Type 1 Receptor Blocker (AT1 RB), β receptor blocker, and diuretics. Those who with secondary arterial hypertension, congenital heart disease, dilated, hypertrophic or restrictive cardiomyopathy, valvular heart diseases, pulmonary hypertension, coronary heart disease (including Ischemic cardiomyopathy), severe heart failure, lipid metabolism disorders, acute and chronic liver disorders were excluded. All patients were provided with an informed written consent. The study protocol was approved by the ethics committee in our hospital. The clinical variables including diabetes mellitus (DM), alcohol intake, smoking status, weight, height, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) were acquired
89
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
from the medical charts. The levels of serum creatinine (sCr), total cholesterol (TC), total triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and blood glucose were acquired.
The measurements of High-sensitivity C-reactive protein (hs-CRP) and serum LOX1 The measurement of High-sensitivity C-reactive protein (hs-CRP) was performed using a commercially available high-sensitivity assay (Roche Diagnostics). Serum sLOX-1 levels were measured by a commercially available enzyme-linked immunosorbent assay kit. The assay is sensitive to the sLOX-1 level of 2.4 pg/mL and above with a coefficient of variation 49.2 g/2.7 m for men and >46.7 g/2.7 m for women [16]. The echocardiography measurement was performed by two experienced echo doctors who were blind to the study protocols. The intra-observer correlation coefficiency for two investigators was 0.925 and 0.903, respectively (both P 0.05). The genotype and allele frequencies of the intron 4 G>A and 3′UTR T>C SNPs were not significantly different between the LVH+ and LVH- groups (P>0.05). However, the genotype and allele frequencies of the 501G>C SNP were significantly different between those two groups. LVH+ patients had a markedly higher frequency of CC genotype than LVH- patients (60% vs.49 %, P=0.007). With the 501GG genotype as reference, multivariate logistic regression analysis showed that the 501CC genotype carriers had a markedly higher risk to develop LVH (adjusted OR=2.444, 95% CI:1.39-4.28, adjusted P=0.002) after adjustment for age, sex, alcohol intake, smoking status, BMI, TG, TC, HDL ,LDL, sCr , BP levels, hs-CRP and sLOX1 levels. The C allele carriers represented a significantly lower risk of developing LVH after adjustment of the above mentioned clinical variables (adjusted OR=1.571, adjusted PA and 3′UTR T>C, and the occurrence of LVH (all P>0.05).
90
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Table 1. The clinical and biochemical characteristic of all enrolled patients is shown in Table 1
Table 2.The genotypes and the allele frequencies of LOX1 gene in two groups
LOX1 haplotypes and LVH The associations between the LOX1 haplotypes and the LVH status were also explored in this study. The D´ value for the studied 3 SNPs was calculated using the SHEsis software. All 3 SNPs were in strong LD (all D´>0.8). The estimated haplotype frequencies of the LOX1
91
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Table 3. LOX1 haplotypes and LVH. (All those frequencyC polymorphism was significantly correlated with the levels of sLOX1 and hs-CRP in this study. The 501CC genotype carriers had markedly increased levels of sLOX1 and hs-CRP compared to the 501GG and 501GC carriers (all PT SNP is located at the 3’ untranslated region of mRNA that has been shown to modulate the regulation of gene expression [27]. Its correlation to severity of AMI and CAD has also been proposed according to a number of research studies [27, 33, 34]. The intron 4 G>A SNP has been previously studied due to its occurrence in linkage disequilibrium (LD) with the 501 G>C and 3’UTR C>T SNPs in the OLR1 gene [30]. The association of polymorphisms of the OLR1 gene and risks to develop vascular diseases, however, is still inconclusive. The 501G>C SNP, for example, failed to show correlation in the development of the ischemic cerebrovascular diseases (CVD) [36]. Our study was not able to establish the statistical association between the SNPs, Intron 4 and 3’UTR, and LVH in the EH patients. This may be due to the size of sample that did not reach the power of calculation. In line with a report from Chen et al., three SNPs we studied were in significant LD and were presented with similar allele frequencies (i.e., Intron 4>G 48.3%, 501 >G 48% and 3’UTR >T 48%). These frequencies are comparable to data generated from studies on non-Hispanic white populations, neverthelss, vastly different from the African American populations [27]. Evidence of LD has been widely reported between the polymorphisms of the LOX1 gene. Three common haplotypes account for 85% of the observed OLR1 haplotypes among the Centre d'Etude du Polymorphisme Humain (CEPH) individuals, who are representative of the European American population from the HapMap project (10 SNPs) [37]. Three LD blocks have been described [30]. Here, we, for the first time, report the similar allele frequencies of the intron 4 G>A, 501 G>C and 3’UTR C>T SNPs in the LOX1 gene between the Chinese population and certain Western population. In addition, the haplotypes (intron 4-501-3’UTR), A-C-C and G-C-T, showed significant correlation to the development of LVH in EH patients, which is consistent with the finding that the LVH+ patients had a markedly higher frequency of the CC genotype compared to the LVH- patients (P=0.007). This may provide evidence of using the 501 G>C SNP as a solo genetic marker to monitor the EH patients for their risk to develop LVH. We also found that the LOX1 501CC genotype carriers had significantly increased sLOX1 and hs-CRP levels compared to the 501GG and 501GC carriers. Furthermore, not only the sLOX but also the hs-CRP levels were significantly higher in the LVH+ group compared to the LVH- group. The sLOX-1 level, however, may be a better parameter than hs-CRP to
93
Cellular Physiology and Biochemistry
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
differentiate the LVH+ patients from the LVH- patients based on the ROC curves. These experimental results correlate to close functional partnership of LOX1 and CRP that has been well studied in their pro-atherogenic effects on vascular cells [16, 38-41]. Among all, a recent study suggested that L5, a subfraction of plasma LDL, CRP and the LOX-1 may constitute a positive feedback loop that contributes to endothelial dysfunction [39]. LOX-1 along with Fcγ receptors functions as a receptor for CRP [42]. CRP elicits oxidative stress and compromises vasomotor function on porcine coronary arterioles via LOX-1 activation [38]. In addition, CRP promotes the release of soluble LOX-1 from macrophages by activating tumor necrosis factor alpha (TNF-α) converting enzyme [39] and increases vascular permeability through direct binding to LOX-1[42]. On the other hand, LOX-1 mediated upregulation of a thrombogenic protein, plasminogen activator inhitor-1 (PAI-1) in arterioles by CRP [38]. LOX-1 may be also involved in CRP-induced complement activation, and thus may serve to locate the site of CRP-induced complement activation and inflammation [42]. Those emerging pieces of evidence could facilitate our understanding to the mechanisms involved in the regulation of the LOX1 501 SNP on the sLOX1 and hs-CRP levels among EH patients. Several limitations should be addressed in this study. Firstly, this is a single center study on the Chinese population. A validation cohort is necessary to confirm the association between the serum LOX1 levels and the LOX1 SNPs among EH patients with LVH. Secondly, the findings of this study only indicate the association between the LOX1 polymorphisms and the serum LOX1 levels among EH patients with already developed LVH. Ideally, the longitudinal echocardiography data is required to determine if a genotype as a biomarker is predictive of the progression and development of LVH in EH patients. Taken together, data from our study indicates that the LOX1 501 >C SNP as well as the LOX1 haplotypes, A-C-C and G-C-T, which carry this particular SNP, are significantly associated with the incidence of LVH among the EH patients. The sLOX-1 level may also serve as a biomarker to monitor EH patients in the development of LVH. Both the prospective and larger scale studies are warranted to verify our findings in order to apply into clinical practice. References
1
2 3 4
5 6
7
8
Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R: Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008;26:1602-1611. Petrovic D, Stojimirovic B: [Left ventricular hypertrophy in patients treated with regular hemodialyses]. Med Pregl 2008;61:369-374. Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 1994;8:S549-556. Tovillas-Moran FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, Dalfo-Baque A, Galceran JM, Coca A: [Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care]. Med Clin (Barc) 2010;135:397-401. Wang Y, Hou X, Li Y: Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects. J Biomed Sci 2010;17:23. Zhan S, Liu M, Yao W, Hu Y, Li L, Zhu G, Sun N, Dai L: [Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2002;23:182-185. Varis JP, Puukka PJ, Karanko HM, Jula AM: Risk assessment of echocardiographic left ventricular hypertrophy with electrocardiography, body mass index and blood pressure. Blood Press doi:10.3109/080 37051.2013.803313. McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, Sorof JM, Portman RJ: Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension 2007;50:392-395.
94
Cellular Physiology and Biochemistry 9 10 11
12 13 14
15 16
17
18 19 20
21
22
23
24
25
26
27
28
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Bangalore S, Yao SS, Chaudhry FA: Usefulness of stress echocardiography for risk stratification and prognosis of patients with left ventricular hypertrophy. Am J Cardiol 2007;100:536-543. Koziolova NA, Shatunova IM, Lazarev IA: [Risk factors of development of left ventricular hypertrophy in patients with hypertensive disease with high compliance to treatment]. Kardiologiia 2012;52:25-30. Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin-Duran R, Hurle MA, Nistal JF: Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009;46:526-535. Mirotsou M, Dzau VJ, Pratt RE, Weinberg EO: Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol Genomics 2006;27:86-94. Kurbanova D, Eliseyeva M: Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars 2010;38:466-472. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA: Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest 2013; 73:75-81. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS, Ferrante AW, Mital S: Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 2008;14:760-767. Xu HY, Hou XW, Wang LF, Wang NF, Xu J: Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010;335:13-17. Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S: Protective role of granulocyte colonystimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 2009;187:40-44. Inoue N, Fujita Y, Sawamura T: [Progress in the research on Lox-1 and its clinical relevance]. Nihon Yakurigaku Zasshi 2006;127:103-108. Al-Banna N, Lehmann C: Oxidized LDL and LOX-1 in experimental sepsis. Mediators Inflamm 2013;2013:761789. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T: Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-294. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colonystimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100:899-902. Kang BY, Hu C, Ryu S, Khan JA, Biancolella M, Prayaga S, Seung KB, Novelli G, Mehta P, Mehta JL: Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics 2010;42:42-54. Hu C, Dandapat A, Chen J, Fujita Y, Inoue N, Kawase Y, Jishage K, Suzuki H, Sawamura T, Mehta JL: LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res 2007;76:292-302. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, Mehta JL: Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 2008;283:10226-10231. Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H, Masaki T: Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene. Biochem J 1999;339:177-184. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, McNamara DM, Pauly DF, Sharaf B, Holubkov R, Bairey Merz CN, Sopko G, Bontempo F, Kamboh MI: Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003;107:3146-3151. Hou XW, Yang RQ, Zhong YG, Gao W, Sun SP, Wang NF: G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 2011;10.
95
Cellular Physiology and Biochemistry 29
30
31 32 33
34
35
36 37 38 39
40
41
42
Cell Physiol Biochem 2014;33:88-96 DOI: 10.1159/000356652 Published online: January 17, 2014
© 2014 S. Karger AG, Basel www.karger.com/cpb
Xu et al.: LOX1 Gene Polymorphism Predicts LVH in Hypertension
Hou XW, Wang LF, Wang N, Pang D, Hui B, Zhou YL, He X: The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta 2008;388:200-203. Trabetti E, Biscuola M, Cavallari U, Malerba G, Girelli D, Olivieri O, Martinelli N, Corrocher R, Pignatti PF: On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 2006;14:127-130. Li JJ, Chen JL: Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005;64:925-929. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003;12:181-187. Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S, Kawana M, Masaki T, Kasanuki H, Sawamura T, Matsuoka R: Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-250. Ohmori R, Momiyama Y, Nagano M, Taniguchi H, Egashira T, Yonemura A, Nakamura H, Kondo K, Ohsuzu F: An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 2004;27:641-644. Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi-Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, Tate S: Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 2005;13:905-917. Hattori H, Sonoda A, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N: G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res 2006;1121:246-249. Meucci MA, Marsh S, Watters JW, McLeod HL: CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 2005;6:59-63. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L: Selective Activation of LOX-1 Mediates C-Reactive Protein Evoked Endothelial Vasodilator Dysfunction in Coronary Arterioles. Circ Res 2013;114:92-100. Chu C-S, Wang Y-C, Lu L-S, Walton B, Yilmaz HR, Huang RY, Sawamura T, Dixon RAF, Lai W-T, Chen C-H, Lu J: Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor. PLoS ONE 2013;8:e70533. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH: Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-627. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WS, Yang CY, Chen CH: Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57:158-166. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T: Lectin-like Oxidized LDL Receptor 1 Is Involved in CRP-Mediated Complement Activation. Clin Chem 2011;57:1398-1405.
96
Copyright: S. Karger AG, Basel 2014. Reproduced with the permission of S. Karger AG, Basel. Further reproduction or distribution (electronic or otherwise) is prohibited without permission from the copyright holder.
